Purpose: To develop a measure for use with adults with epilepsy and mental retardation, capable of assessing both clinical and care concerns and of quantifying treatment outcomes.
There is need to go beyond seizure counts in the assessment of epilepsy (1) . Although psychosocial morbidity has been recognised for some time (2, 3) , there is a dearth of reliable and valid ways in which to measure such factors. It cannot be assumed that good psychosocial outcome will be associated even with the attainment of a seizure-free state (4) , and seizure frequency may not be the best predictor of how people with epilepsy cope (5) . Furthermore, there are people with epilepsy for whom seizure control is elusive, and for whom measurement of other factors seems particularly relevant.
People with mental retardation represent a sizeable subgroup and an even higher proportion of those whose seizures are difficult to manage. They have a population prevalence rate for epilepsy some 20 to 30 times higher than that of the general population (6, 7) and present challenges in diagnosis and management. Presentation is often compounded by health problems, stereotypies, automatisms, and drug-induced motor symptoms, and the patient is usually unable to report seizure information (8) . The clinician normally relies on descriptions from carers, who may change from consultation to consultation. It also can be difficult for carers to differentiate seizures and to maintain accurate records. Epilepsy in people with mental retardation is often refractory to effective treatment (9) . Furthermore, aggressive management may result in diminishing returns in terms of seizure abatement, and lead to unwanted effects in those who can ill afford further mental impairment.
Recent reviews suggest few measures suitable for use with this population (10, 11) . The Washington Psychosocial Seizure Inventory (12) was designed to measure emotional and interpersonal adjustment. Although not specifically validated for use with people with mental retardation, nevertheless, these dimensions are relevant to this population. The Epilepsy and Learning Disabilities Quality of Life (13) scale (ELDQOL) was developed for use with children with Lennox-Gastaut syndrome and has content validity, although not related to any conceptual model of "quality of life." Modest test-retest coefficients (r ‫ס‬ 0.67-0.87) and internal consistency (␣ ‫ס‬ 0.71-0.84) have been reported. The ELDQOL is relatively lengthy, perhaps more suited to overview than to outcome evaluation, as it is possible to derive component scores only from a few subsections.
Some years ago we began a research program to develop an outcome scale for use with adults with mental retardation. We tested a method comprising qualitative and psychometric components, and published our pilot Epilepsy Outcome Scale (EOS) in 1998 (14) . The EOS generates a total score and four subscale scores reflecting carers' concerns about "seizures," "medication," "injury," and "daily living" and has sound psychometric properties. Cronbach's ␣ for the total scale was 0.92 (0.72-0.91 for subscales), and test-retest reliability was 0.86. The EOS is being used in a number of controlled trials of antiepileptic drugs (AEDs).
We present results from recent studies on a much larger sample of respondents (n ‫ס‬ 384) and patients (n ‫ס‬ 186). Importantly, the new scales (Glasgow Epilepsy Outcome Scales; GEOS) integrate concerns expressed by clinicians and health practitioners, as well as family and staff carers. Whilst retaining our method to ensure content validity, internal consistency, and factor structure, we also have completed analyses of discriminant and concurrent validity.
METHODS AND RESULTS
Our aim was to develop and field test a measure for use with adults with epilepsy and mental retardation, capable of summarising clinical and care concerns, and of quantifying treatment outcomes. Recognised methods for scale construction were used, and because these are iterative procedures, methods and results are integrated for the purpose of clarity.
Sample
A database was compiled with information on 685 adults in Glasgow and Edinburgh. Clinical sources were two epilepsy clinics in Glasgow and four Community Learning Disability Teams covering Greater Glasgow. Subjects living around Edinburgh were drawn from specialist clinics for epilepsy plus mental retardation. Inclusion criteria were (a) adults aged 18-60 years; (b) with at least mild mental retardation according to World Health Organisation definitions (incomplete or arrested development of the mind, with diminished ability to adapt to the social environment, and IQ Յ 69); (c) epilepsy confirmed by clinical history; (d) having at least one seizure per month on average; and (e) a carer (family and/or staff) who had participated in care decisions for at least the preceding 3 months. Exclusions were deteriorating health, particularly neurologic disorder, and nonepileptic seizure disorder.
Development of the GEOS

Derivation of the item pool
The first phase comprised development of a draft measure to reflect the principal concerns that carers and health practitioners have about epilepsy in people with mental retardation. As in our pilot (14) , focus group techniques (15) were used to identify the impact epilepsy was perceived to have. We selected a convenience sample of 48 carers (21 family carers, 27 staff carers) and 46 health practitioners (eight medical practitioners with an interest in epilepsy, 18 nurses, 10 paramedical professionals, six clinical psychologists, four pharmacists) to participate in focus groups, each comprising four to nine participants, plus an experienced facilitator. The 21 groups (five family, seven staff carer, nine practitioner) followed a common protocol. Participants first completed the Epilepsy Knowledge Profile (16) (EKP), a scale of 55 factual statements on medical and social aspects of epilepsy to help promote general discussion about epilepsy. Then they completed a pro forma about the individual on whom they were going to report their concerns. This was to ensure focusing on a specific person whose needs were known to them. Participants recorded their three principal concerns on the form, and these were presented and discussed in the group. The facilitator helped clarify and record all issues raised during discussion.
This process yielded 374 items of concern from family carers, 209 from staff carers, and 424 from health practitioners. All items were entered on a NUD*IST (17) database for thematic, qualitative analysis. Duplicate or idiosyncratic items were removed, those with similar content rationalised, and themes were progressively developed. This resulted in 100 items for staff, 96 for family carers, and 114 for practitioners, which were used to construct separate, first versions of the GEOS. Items were randomised, and Likert scales added using a 5-point scale comprising 0, never a concern; 1, occasionally a concern; 2, fairly often a concern; 3, often a concern; and 4, very often a concern.
Refinement of the item pool
Draft scales were mailed to the derivation samples who had attended focus groups plus additional carers identified from the database. Completed scales were returned by 46 staff, 36 family carers, and 42 practitioners (91%) and were analysed using correlational methods to reduce the number of items to the most relevant concerns. Strict criteria for item removal were used: if (a) the item scored within the bottom 25% of the item scores, (b) the item scored 0, never a concern, in >75% of completed measures; (c) the corrected item-total correlation was r ‫ס‬ <0.4; (d) Cronbach's ␣ was increased when the item was deleted, and (e) item content of two retained items was similar, and the correlation between them was r ‫ס‬ >0.6. This reduced staff carer items to 48, family carer items to 62, and practitioner items to 63.
Because our purpose was to develop a single scale, which could be completed by any of the "stakeholders" in care and so permit perspectives on care to be compared, the next stage was to merge items. The 173 items (i.e., 48 + 62 + 63), therefore, were examined for overlap, leading to 113 items being selected for a validation phase in which all participants would rate all derived concerns. Before field-testing, four subscales were defined representing the broad concerns raised at discussion groups and the overarching themes from qualitative analysis. These were "concerns about seizures," "concerns about treatment," "concerns about caring," and "concerns about social impact."
Field-testing of the GEOS
This comprised a comprehensive field trial of the scale in a sizeable clinical sample. A structured interview was completed with the principal carer to gather information on the person's epilepsy, physical and mental well-being, and daily living skills. Measures comprised the Vineland Adaptive Behaviour Scales (18) (V-ABS), the checklist from the Psychiatric Assessment Schedule for Adults with Developmental Disability (19) (PAS-ADD), the Aberrant Behaviour Checklist (20) , and the ELDQOL (13) . Carer coping was assessed using the Caregiver Strain Index (21) (CSI), the Hospital Anxiety and Depression Scale (22) (HADS), and knowledge of epilepsy was measured by the EKP (16) .
The database was used to select 250 patients using SPSS (23) random number sequences. Of these, seven carers refused participation, and attempts to make contact with 54 were unsuccessful. Therefore, agreement to participate was reached for 189 participants; however, three were excluded because of age (n ‫ס‬ 2) and nonepileptic seizures (n ‫ס‬ 1). From the 186 (74%) retained interviews, 132 family and 173 staff carers were identified to complete the GEOS, which was returned completed by 83 (63%) and 141 (82%) carers, respectively. Clinicians (mainly medical practitioners, but also epilepsy nurse specialists and neuropsychologists) involved in epilepsy management had been identified for 172 of the 186 individuals. Of these, 160 (93%) returned the scales.
Descriptive and clinical information
Nearly half the patients lived with relatives (n ‫ס‬ 76, 41%), and a similar number lived with staff carers (n ‫ס‬ 84, 45%). The remaining 26 (14%) lived in an institutional setting. One hundred eighteen (63%) lived in the Glasgow area, and 68 (37%) in the Edinburgh area, consistent with population estimates of people with mental retardation. As anticipated, there were more males (n ‫ס‬ 108; 58%) than females (n ‫ס‬ 78; 42%). Mean age was 39 years in care environments, significantly older than the mean of 31 years for those living with family [Mean difference, 7.69 years; confidence interval (CI) 95%, 4.45-10.9; p < 0.01]. Level of mental retardation was assessed from clinical sources. Three fourths (n ‫ס‬ 139) had at least moderate mental retardation (IQ range, 35-40 to 50-55), of whom 27 (15%) were profoundly retarded (IQ level <20-25). All subjects were rated on the V-ABS as having a deficit in adaptive daily living skills, with 14 (8%) exhibiting borderline deficit, 20 (11%) mild deficit, eight (4%) moderate deficit, 15 (8%) severe deficit, and 128 (69%) profound deficit. No significant difference was found between those living at home and those "in care." One fourth (n ‫ס‬ 47) were not ambulant, 27 (15%) had hearing impairment, 62 (33%) visual impairment, and 55 (30%) had no speech.
Epilepsy was most often managed by an epilepsy specialist/consultant neurologist (68%) and/or a general medical practitioner (GP, 49%). In many cases (n ‫ס‬ 78, 42%), both the neurologist and GP were involved. In 14 (8%) cases, epilepsy was not currently managed by any clinician. Polypharmacy was common. Sixty-two (33%) patients were prescribed two AEDs, 58 (31%) three AEDs, and 16 (9%) four or more. Fifty (27%) patients were receiving AED monotherapy. Mean age at onset of epilepsy was 4.5 years, ranging from birth to 38 years. Seizure frequency varied enormously, ranging to >2,000 seizures per year. Forty (22%) patients had seizures at least daily, 63 (35%) at least weekly, and 56 (31%) had at least one seizure per month. Detailed descriptions of seizures were obtained from the principal carer, including seizure patterns, nature of onset, duration, movements, incontinence, loss of consciousness/ responsiveness, injuries, and postictal behaviours. These were rated blind by an experienced epileptologist to obtain an assessment of likely seizure types. Seizure frequency was based on carer estimates and did not discriminate between the various types of seizures. Further details of seizure activity were obtained from the ELDQOL subdomain on "seizure severity."
Carer characteristics
Interviews were undertaken with the principal carer (78 family members and 108 staff carers). Mean age of family carers was 57 years compared with 37 years in staff carers (mean difference, 19.4 years; CI 95%, 16.0-22.8 years). Family carers had cared for the person for significantly longer, a mean of 28.7 years compared with 5.8 years in staff carers. All carers, however, had cared for the individual for Ն3 months. Epilepsy knowledge did not differ between staff and family carers. On the EKP medical subscale, the mean score was 27 (79% correct), and on the social subscale, it was 15.8 (71% correct). These scores are consistent with those reported in another recent study (14) . Levels of caregiver strain were assessed only in family carers, as staff work with several people, and scores could not be linked to a specific person. Forty-three (53%) carers scored above the norm for "higher than average stress" on the CSI. Using cut-off scores of 10 and 8, respectively, on the HADS, 24 (34) family carers achieved "caseness" on anxiety, and 13 (18%) reached "caseness" for depression.
Psychometric evaluation of the GEOS Data were analysed using SPSS software. The reliability of the scale was investigated in terms of its internal consistency, and confirmatory principal components analysis (Varimax rotation) was used to assess the struc- ture and integrity of the four subscales. Concurrent and discriminant validity was assessed using t tests, one-way analyses of variance (ANOVAs), and correlation methods, as appropriate.
Final content validation
A total of 384 GEOS forms was available (113-item version); from 160 clinicians, 141 staff carers, and 83 family members. This data set was investigated first to determine which items should be retained. Inclusion/ exclusion criteria used earlier were reapplied, leading to the retention of 90 items, distributed across subscales as follows: concerns about seizures (30 items), concerns about treatment (26 items), concerns about caring (14 items), and concerns about social impact (20 items) ( Table 1) .
Principal components analysis
The subscales of the GEOS-90 developed from thematic analyses paralleled the structure of our pilot scale (14) . To investigate the factor structure of these scales, principal components analysis (PCA) with orthogonal (Varimax) rotation was used. [In PCA, a sample size of >300 is generally regarded as "good" (24, 25) .] Items were regarded as loading significantly if they achieved a value Ն0.45, and factors yielding an eigenvalue >1 were retained (26) . Factor loadings are presented in Table 1 , and results of PCA in terms of explained variance can be found in Table 2 . Five factors explained a total of 68% of variance in "concerns about seizures." "After-effects of seizures" contributed the highest proportion of explained variance (27%), but all factors contributed significantly.
Four factors explained 66% of variance in "concerns about treatment," all of which contributed similarly in terms of effect. For "concerns about caring," three factors explained >70% of variance, with "achieving a balance" (in terms of independence and supervision) being the strongest factor. "Concerns about social impact" comprised three contributing factor scales explaining 73% of variance. Inspection of loadings reveals that items loaded strongly and positively, with 52% being >0.70 and 76% being >0.60. Most items also loaded at Ն0.45 on only one factor, which demonstrates a relatively pure factor solution.
Internal consistency
Reliability of the GEOS-90, its derived subscales, and their component structures was assessed using Cronbach's ␣. Table 2 demonstrates that ␣ for the whole scale was very high at 0.98, with subscale ␣ coefficients ranging from 0.937 to 0.963. Factor scale ␣ values were also strong (Ն0.82). Table 2 also presents item-deletion data, which indicate the stability of the measure when items are systematically eliminated. The widest range of 0.793 to 0.956 was for "injury risks"; however, this is within acceptable limits for internal consistency, for which a criterion of 0.80 is the accepted standard (27) .
Intercorrelation of scales
The four subscales correlate strongly with the total score (r Ն 0.88) and also intercorrelate in the range r ‫ס‬ 0.71 to 0.79. Average interitem correlations are presented in Table 2 , indicating a somewhat lower level of shared variance within scales (0.573 to 0.687). As might be expected, factor scales also correlate significantly within the subscales from which they derive: "concerns about seizures" (range of r ‫ס‬ 0.561-0.737), "concerns about treatment" (0.519-0.778), "concerns about caring" (0.657-0.748), and "concerns about social impact" (0.552-0.774).
Discriminant and concurrent validity
Comparison of clinician, family carer, and staff carer are beyond the scope of this article, but are presented elsewhere along with some normative data (28) . However, it is possible to consider the extent to which the GEOS-90 discriminates dimensions of clinical importance. Table 3 reveals that mean GEOS-90 total scores were higher in patients with more than one type of seizure, in those receiving AED polytherapy (both p Յ 0.05), and in those prescribed rectal diazepam (DZP; p < 0.005). Estimated seizure frequencies were also significantly different (p < 0.005), with Scheffé post hoc tests indicating that people with seizures on a daily basis had higher total scores than did those with seizures monthly or less often (p < 0.05). There also was a modest nonparametric correlation between estimated number of seizures per month and GEOS-90 total score (rho ‫ס‬ 0.414; p < 0.001; n ‫ס‬ 155).
Although there is no "gold standard" for measuring concerns about epilepsy in this population, components of available measures may be used to consider concurrent validity. On the ELDQOL, GEOS-90 total scores were significantly different on two comparisons. Having little or no control over seizures and falling during seizures were associated with higher mean total scores (p < 0.05). Interestingly, the ELDQOL seizure severity index did not correlate with the GEOS-90, although the ELDQOL side-effect profile was modestly correlated with the drug side-effect factor score on GEOS-90 (rho ‫ס‬ 0.183; p ‫ס‬ 0.018; n ‫ס‬ 157).
Development of a short-form version of the GEOS
As the GEOS-90 subscales intercorrelate at an average of ∼0.75, the scale comprises around 56% shared variance (R 2 ). We decided, therefore, to explore development of a short-form version. To establish the best subset of items, a step-wise linear regression procedure was applied to each GEOS-90 subscale. This identified items, in order of explanatory influence, until no significant additional variance was explained. Comparison was then made amongst solutions to ensure retention of at least two items from each of the original factors. Thus 10 items were retained on "concerns about seizures" (Adj. R 2 ‫ס‬ 0.96), nine on "concerns about treatment" (Adj. R 2 ‫ס‬ 0.96), eight on "concerns about caring" (Adj. R 2 ‫ס‬ 0.97), and eight on "concerns about social impact" (Adj. R 2 ‫ס‬ 0.97; all values of p < 0.0001); a total of 35 items. Therefore we will refer to the scale as the GEOS-35 (see Table 1 ). Standardised beta coefficients demonstrated that each variable contributed to its derived subscale (all values of p < 0.001). Cronbach ␣ for these subscales ranged from .89 to .91 (Table 2) . GEOS-35 subscales correlated around 0.98 with respective GEOS-90 subscales and intercorrelated in the range 0.68 to 0.78. Data presented in Table 3 show that the short form has concurrent and discriminant validity comparable with the GEOS-90. 
DISCUSSION
The GEOS-90 is a successor to our pilot scale (14) and offers considerable potential in quantifying the types and degrees of concerns associated with the treatment and care of people with epilepsy and mental retardation. Content was derived directly from those involved in the care process. Our protocol generated 1,007 items, from focus groups involving 48 carers and 46 health professionals, which were refined by an iterative process to 90 items. The perspective of the person with epilepsy is more difficult to establish in people with intellectual deficits. However, a separate study, with 50 individuals with mild to moderate mental retardation, will form the basis of another report (29) . In that context, we will be able to examine the interrelationship between the GEOS-90 and the GEOS-client version.
A particular strength of the GEOS-90 is its range of scales. The four principal subscales, concerns about "seizures," "treatment," "caring," and "social impact," were derived from thematic modelling and reflect the structure of the pilot scale. Uniformly high ␣ values for the scale and its subscales were obtained (all >0.93); therefore the GEOS-90 can be regarded as internally consistent. Factor scales were derived from PCA. More than three fourths of factor loadings were >0.60, and all factors explained a sizeable amount of variance (66-73%). Factor scales also were internally consistent (␣ range, 0.82-0.93). The GEOS-90, therefore, provides a flexible tool with 20 indices of measurement (total, four subscales, and 15 factor scales). Interitem correlations suggest ∼35% shared variance within subscales. However, because the between-subscale intercorrelation matrix revealed moderate associations (∼0.75), indicating >50% shared variance, a short-form version also was developed using regression models. This resulted in the GEOS-35, which comprises a representative subset of items with similarly robust psychometric properties. A separate article will present comparative analyses of clinician, staff, and family carer ratings on the GEOS-90 and GEOS-35, and normative data for these rater groups (28) . Work also is under way to establish test-retest reliabilities. It is worth noting, however, that test-retest reliability for the pilot scale was 0.86.
Our research began in recognition of the lack of validated measures for use in this population (10, 11) . Therefore external validation of our scales is problematic. Given the absence of an acknowledged criterion, we attempted preliminary evaluation of discriminant and concurrent validity. Our results, however, should be interpreted with caution. Modestly significant differences in GEOS-90 and GEOS-35 total scores were obtained on a number of clinical dimensions, including seizure frequency, single versus multiple types of seizures, monotherapy versus polytherapy, and use of emergency medication. Of course, the ability of GEOS to discriminate clinical measures at only a modest level actually supports the contention that epilepsy concerns are more broadly based than are traditional emphases, such as on seizure counting (1) . Taking the ELDQOL as the best available concurrent measure, we found modest relation to measures of control over seizures and falling during a seizure. We did not find significant covariation between the ELDQOL seizure severity scale and GEOS scores; thus further work might usefully explore concepts of seizure severity in this population.
The ease of use of the GEOS scales is a practical strength. Both the GEOS-90 and GEOS-35 have a straightforward structure, using 5-point ratings. The former can be completed in 10 min and the latter in <5 min, yet both comprehensively cover salient issues. We suggest the GEOS-90 might be useful clinically for initial descriptive quantification of concerns about epilepsy and in research protocols. The GEOS-35 has repeated measurement utility in routine practice, as a "process" measure of change, adjunctive to estimates of seizure frequency, and in trials of AED compounds. The fact that we succeeded in getting >90% of the clinicians approached to complete the longer version is testimony not only to the GEOS acceptability to clinicians, but also reflects its perceived relevance to their patients. We had a similarly high return rate from carers. Work is ongoing to investigate sensitivity of outcome measurement, that is, capacity to detect change over time, and in response to treatment.
